RM-MET / Metabolic and incretin signalling
Maridebart Cafraglutide
Also known as: MariTide · AMG 133
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Maridebart cafraglutide is an antibody-peptide conjugate: an anti-GIP-receptor antibody carries GLP-1 agonist peptide domains. The architecture is the identity.
Evidence position
Published randomized phase 2 and mechanistic human data support Grade B. It must be separated from simple peptide powders and from dual agonists such as tirzepatide.
What the record does not establish
An AMG 133 or MariTide label on a powder cannot establish the complex conjugate architecture, biologic function or equivalence to the clinical material.
Sources
- 01Once-monthly Maridebart Cafraglutide phase 2 trialPubMed
- Shows
- Randomized 52-week human phase 2 outcomes
- Does not show
- Sponsor-funded trial of a defined antibody-peptide conjugate; not evidence for a free peptide
- 02AMG 133 preclinical and phase 1 mechanism studyPubMed
- Shows
- Conjugate architecture, receptor design and phase 1 context
- Does not show
- Mechanistic and early clinical evidence does not establish outside-product equivalence
- 03Maridebart Cafraglutide phase 2 registry recordClinicalTrials.gov
- Shows
- Official aliases, study arms, status and outcome definitions
- Does not show
- Registration does not establish approval or material quality
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.The New England journal of medicine / 2025 Sep 4PMID 40549887 / DOI 10.1056/NEJMoa2504214
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes care / 2024 Nov 1PMID 38843460 / DOI 10.2337/dci24-0003
- A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.Nature metabolism / 2024 FebPMID 38316982 / DOI 10.1038/s42255-023-00966-w
- Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.Nature reviews. Endocrinology / 2023 AprPMID 36509857 / DOI 10.1038/s41574-022-00783-3
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides / 2025 MayPMID 40081498 / DOI 10.1016/j.peptides.2025.171380
CLINICALTRIALS.GOV / FOUND RECORDS
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NOT_YET_RECRUITING / PHASE3 / AmgenNCT07684144 / DIRECT intervention MATCH: Maridebart Cafraglutide
- Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsCOMPLETED / PHASE1 / AmgenNCT07226778 / DIRECT intervention MATCH: Maridebart Cafraglutide
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRECRUITING / PHASE3 / AmgenNCT07037459 / DIRECT intervention MATCH: Maridebart Cafraglutide
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRECRUITING / PHASE3 / AmgenNCT07037433 / DIRECT intervention MATCH: Maridebart Cafraglutide
- Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusCOMPLETED / PHASE2 / AmgenNCT05669599 / DIRECT intervention MATCH: Maridebart Cafraglutide